Mimedx (MDXG) EBIT (2011 - 2026)
Mimedx (MDXG) posted EBIT of -$18.5 million for Q2 2026, down 15.06% sequentially from -$16.0 million in Q1 2026, and down 249.28% YoY from $12.4 million in Q2 2025.
Mimedx (MDXG) EBIT (2011 - 2026) Analysis & Trends
Mimedx has reported EBIT for 16 years, with the latest figure at -$18.5 million in Q2 2026.
- Quarterly EBIT fell 249.28% year-over-year to -$18.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $8.8 million (down 79.57% YoY) and the FY2025 annual result came in at $63.9 million, up 8.53% from the prior year.
- EBIT retreated to -$18.5 million in Q2 2026 per MDXG's latest filing, from -$16.0 million in the prior quarter.
- Over five years, EBIT peaked at $23.4 million in Q2 2024 and troughed at -$18.5 million in Q2 2026.
- A 5-year average of $6.1 million and a median of $11.1 million in 2023 frame the typical range for EBIT.
- The sharpest annual moves came in 2022 and 2024: EBIT tumbled 2250.24% in 2022, then soared 3981.76% in 2024.
- Over 5 years, EBIT stood at $11.3 million in 2022, then soared by 36.95% to $15.5 million in 2023, then dropped by 28.64% to $11.1 million in 2024, then jumped by 90.67% to $21.1 million in 2025, then tumbled by 187.61% to -$18.5 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$18.5 million, -$16.0 million, and $21.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Mimedx | 622.24 Mn | 486.40 Mn | 44.38 Mn | -18.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.47 Mn |
| Mar 31, 2026 | -16.05 Mn |
| Dec 31, 2025 | 21.08 Mn |
| Sep 30, 2025 | 22.19 Mn |
| Jun 30, 2025 | 12.37 Mn |
| Mar 31, 2025 | 8.25 Mn |
| Dec 31, 2024 | 11.05 Mn |
| Sep 30, 2024 | 11.16 Mn |
| Jun 30, 2024 | 23.45 Mn |
| Mar 31, 2024 | 13.20 Mn |
| Dec 31, 2023 | 15.49 Mn |
| Sep 30, 2023 | 11.12 Mn |
| Jun 30, 2023 | 10.84 Mn |
| Mar 31, 2023 | -340,000.00 |
| Dec 31, 2022 | 11.31 Mn |
| Sep 30, 2022 | -7.10 Mn |
| Jun 30, 2022 | -9.64 Mn |
| Mar 31, 2022 | -9.30 Mn |
| Dec 31, 2021 | 1.29 Mn |
| Sep 30, 2021 | -1.08 Mn |